U.S. pharma giant copyright scrapped two experimental weight loss drugs last yr—a at the time-every day capsule, lotiglipron, on account of elevated liver enzymes as well as a twice-day-to-day tablet, danuglipron, because of robust Uncomfortable side effects—but CEO Albert Bourla has said the company is set to “Participate in and gain” with